Latest Genelex Corporation Stories

2013-12-17 23:23:52

New team includes experts in patient care, medical technology, reimbursement and pharmacology focused on enabling genetics-based prescribing at the point of care. Seatte, WA (PRWEB) December 17, 2013 Genelex, a pioneer in personalized medicine and genetics-based medication management, today announced formation of its Clinical Advisory Board. The diverse group of experts will help inform the development and clinical utility of the YouScript® Personalized Prescribing System, which...

2010-08-26 08:00:00

SEATTLE, Aug. 26 /PRNewswire/ -- The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines. Research shows the majority of patients have one or more defects in the genetic coding for these enzymes, greatly increasing their risk of treatment...

2010-06-08 08:00:00

SEATTLE, Wash. and LEXINGTON, Mass., June 8 /PRNewswire/ -- The first-ever comprehensive personalized prescribing services company has been formed with the merger of Seattle-based Genelex Corporation and Lexington, Massachusetts-based Mental Health Connections, Inc. (MHC), signaling a significant advance in personalized medicine. "Personalized prescribing, which is essential to the practice of personalized medicine, requires both Genelex's DNA Drug Sensitivity Testing(TM) and MHC's...

2009-10-01 09:30:00

SEATTLE, Oct. 1 /PRNewswire/ -- One hundred eighty thousand women will be diagnosed with breast cancer this year. Eighty thousand will start taking the drug tamoxifen to prevent the recurrence of their ER (estrogen receptor) positive breast cancers. The treatment is successful in two-thirds of the women who take it. Genelex Corporation (Seattle) is now offering Tamoxitest(TM) that could improve this success rate to greater than 90% by addressing both of the common causes of tamoxifen...

2008-10-30 12:00:21

SEATTLE, Oct. 30 /PRNewswire/ -- Nearly one third of breast cancer patients prescribed tamoxifen currently fail treatment. According to the National Foundation for Cancer Research (NFCR), this failure rate can be reduced to less than ten percent, saving 20,000 lives each year, by having patients take a simple DNA test and properly managing their medications. Recent research shows that tamoxifen has to be activated into endoxifen by the liver enzyme CYP2D6. Endoxifen is the medicine that...

Word of the Day
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".